Showing 2131-2140 of 3039 results for "".
- Heidelberg Engineering and RetInSight to Offer AI-Based OCT Fluid Quantification Solutionhttps://modernod.com/news/heidelberg-engineering-and-retinsight-to-offer-ai-based-oct-fluid-quantification-solution/2479136/Heidelberg Engineering and RetInSight announced they intend to interface the RetInSight AI-based fluid monitor application with the Heidelberg Engineering product portfolio, using cloud exchange and application marketplace technologies. RetInSight utilizes a novel, proprietary algorithm, t
- Texas Eye and Cataract Clinic Now Accepting Bitcoin for LASIKhttps://modernod.com/news/texas-eye-and-cataract-clinic-now-accepting-bitcoin-for-lasik-surgery/2479096/Texas Eye and Cataract (TEC) announced that it had begun accepting payments for LASIK procedures via the cryptocurrency Bitcoin. Texas Eye and Cataract said it began accepting Bitcoin to help patients looking for innovative ways to finance their LASIK procedures. “We’ve never b
- Bausch Health Announces Vyzulta is Now Approved In Brazilhttps://modernod.com/news/bausch-health-announces-vyzulta-is-now-approved-in-brazil/2479084/Bausch Health Companies and Nicox announced that Vyzulta (latanoprostene bunod ophthalmic solution), 0.024%, has received regulatory approval from the Brazilian Health Regulatory Agency (ANVISA – Agência Nacional de Vigilância Sanitária). Vyzulta is indicated for the reduction of IOP in pa
- NovaBay Pharmaceuticals’ Avenova Warm Eye Compress is Now Available on Amazon.com and Avenova.comhttps://modernod.com/news/novabay-pharmaceuticals-avenova-warm-eye-compress-is-now-available-on-amazon-com-and-avenova-com/2479042/
- Visus Therapeutics Announces $36 Million Series A Financing to Advance Development of Novel Presbyopia-Correcting Eye Drophttps://modernod.com/news/visus-therapeutics-announces-36-million-series-a-financing-to-advance-development-of-novel-presbyopia-correcting-eye-drop/2478952/Visus Therapeutics announced the close of a $36 million Series A Preferred Stock financing to advance the clinical development program for the company’s lead asset, Brimochol, an investigational drug designed to be a
- Kala Pharmaceuticals Announces Eysuvis Now Covered by Express Scriptshttps://modernod.com/news/kala-pharmaceuticals-announces-eysuvis-now-covered-by-express-scripts/2478871/Kala Pharmaceuticals announced that pharmacy benefit manager Express Scripts has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% to its National Preferred, Basic and High Performance Formularies, effective February 5, 2021. Eysuvis is the first and only prescription therapy appr
- Bausch Health Announces Vyzulta is Now Approved in South Koreahttps://modernod.com/news/bausch-health-announces-vyzulta-is-now-approved-in-south-korea/2478847/Bausch Health Companies and Nicox announced that Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% has received regulatory approval from the Ministry of Food and Drug Safety in South Korea. Vyzulta is indicated for the reduction of IOP in patients w
- Horizon Therapeutics to Acquire Viela Bio to Grow Rare Disease Medicine Portfoliohttps://modernod.com/news/horizon-therapeutics-to-acquire-viela-bio-to-grow-rare-disease-medicine-portfolio/2478819/Horizon Therapeutics and Viela Bio announced the companies have entered into a definitive agreement under which Horizon will acquire all of the issued and outstanding shares of Viela Bio common stock for $53 per share in cash, which represents a fully diluted equity value of approximately $3.05 b
- Rayner Enters Canadian Ophthalmology Markethttps://modernod.com/news/rayner-enters-canadian-ophthalmology-market/2478773/Following the recent approval of incorporation, Rayner announced that is will now be offering the Rayner portfolio of IOLs and injectors directly to Canadian surgeons. The entry into the Canadian market will be led by Wade Allen, Director: Americas, Rayner Surgical Corp. The RayOne Aspheri
- Innovent Announces NMPA Granted New Indication Approvals for Sulinno for the Treatment of Pediatric Plaque Psoriasis and Noninfectious Uveitishttps://modernod.com/news/innovent-announces-nmpa-granted-new-indication-approvals-for-sulinno-for-the-treatment-of-pediatric-plaque-psoriasis-and-noninfectious-uveitis/2478695/Innovent Biologics announced that Sulinno (adalimumab injection), a recombinant human anti-TNF-α monoclonal antibody drug, has been officially approved by the National Medical Products Administration (NMPA) of China for two new indications, including the treatment